Cytokine Assay in Tears of Healthy Children and With Vernal Keratoconjunctivitis: Case Control Study and Monitoring of Cases at 6 Months

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-30

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ocular surface may be the seat of an inflammatory process in many pathology as vernal keratoconjunctivitis. It has been shown that inflammatory cytokines produced by the cells themselves and the constituent cells of the target organ, are the main factors that cause inflammation. The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cytokine Profile of Conjunctivitis, Performed Through Tears Analysis Among Patients Treated With Dupilumab

NCT04066998

Conjunctival Diseases Atopic Dermatitis Side Effect

UNKNOWN NA

HORMONES IN VERNAL KERATOCONJUNCTIVITIS

NCT05038241

Conjunctivitis, Vernal

COMPLETED

The Role of Cytokines and Mast Cell in the Pathogenesis of SLK, Conjunctivochalasis, and Dry Eye

NCT02160327

Superior Limbic Keratoconjunctivitis Conjunctivochalasis Dry Eye

UNKNOWN

Evaluation of the Efficacy and Safety of Tacrolimus Drops in Children With Vernal Keratoconjunctivitis

NCT05076084

Vernal Keratoconjunctivitis

COMPLETED

Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda

NCT01211327

Vernal Keratoconjunctivitis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ocular surface may be the seat of an inflammatory process in many pathology as vernal keratoconjunctivitis. It has been shown that inflammatory cytokines produced by the cells themselves and the constituent cells of the target organ, are the main factors that cause inflammation. The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vernal Keratoconjunctivitis Healthy Children

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

vernal keratoconjunctivitis

The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjonctivitis and in control subjects

Cytokins assay in tears

Intervention Type PROCEDURE

healthy children

The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects

Cytokins assay in tears

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cytokins assay in tears

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Childrens between 3 and 18 years
* Affiliated at system of French social security
* Signed by the holders of parental authority of the sheet and written consent to participate in this study
* First consultation at Clermont-Ferrand Hospital for vernal keratocunjunctivitis

Exclusion Criteria

* Subject suffering from acute or chronic eye disease in which the physician investigator resound with the results: uveitis, glaucoma, retinopathy
* Subject who had undergone eye surgery
* Subject having an infection the day of collection: ENT, digestive, urinary
* Subject with cancer, mental illness or any other condition in which the physician investigator sound informed consent and / or the results
* Pregnant subject
* Subject with contact lenses
* Subject who judged by the investigating physician not enough cooperating to allow a safe collection

Minimum Eligible Age

3 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes